Biomea Fusion (BMEA) to Release Quarterly Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) is anticipated to release its earnings data before the market opens on Monday, March 24th. Analysts expect Biomea Fusion to post earnings of ($1.00) per share for the quarter.

Biomea Fusion Stock Performance

Shares of BMEA opened at $2.87 on Friday. The stock has a 50-day moving average of $3.47 and a two-hundred day moving average of $6.18. The stock has a market cap of $104.01 million, a P/E ratio of -0.72 and a beta of -0.26. Biomea Fusion has a one year low of $2.35 and a one year high of $16.97.

Analyst Ratings Changes

A number of research firms have commented on BMEA. D. Boral Capital reaffirmed a “buy” rating and set a $16.00 target price on shares of Biomea Fusion in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Biomea Fusion in a research report on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Biomea Fusion presently has an average rating of “Buy” and a consensus target price of $29.18.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.